_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear
Raising awareness about glaucoma is crucial in India where it is the leading cause of irreversible blindness with at least 12 million people affected and almost 1.2 million people blind from the disease
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Subscribe To Our Newsletter & Stay Updated
